Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
U.S. Newswire › August 22, 2008
Linked as:
Summary
To: MEDICAL EDITORS
Contact: Charles McAtee, Eli Lilly and Company, +1-317-277-1566; or Eva Freitag, Boehringer Ingelheim, + 49 (6132) 77-2964See the full content of this document
Extract
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
INDIANAPOLIS, Aug. 22 /PRNewswire-FirstCall/ -- Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD). This approval -- the fourth for duloxetine in Europe -- was issued on 28 July following an initial positive opinion issued by the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) on 26 June 2008.
The approval is based upon the r...See the full content of this document
Sponsored links
